Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 95
Price : Single User: US $ 2000  US $ 1600 Corporate User: US $ 6000  US $ 4500
Inquire Before Buying
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's, ‘Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016', provides an overview of the Alpha- Antitrypsin Deficiency pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency

  • The report reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Alpha- Antitrypsin Deficiency therapeutics and enlists all their major and minor projects

  • The report assesses Alpha- Antitrypsin Deficiency therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Alpha- Antitrypsin Deficiency Overview 9
Therapeutics Development 10
Pipeline Products for Alpha- Antitrypsin Deficiency - Overview 10
Alpha- Antitrypsin Deficiency - Therapeutics under Development by Companies 11
Alpha- Antitrypsin Deficiency - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Alpha- Antitrypsin Deficiency - Products under Development by Companies 16
Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development 18
Adverum Biotechnologies, Inc. 18
Alnylam Pharmaceuticals, Inc. 19
Applied Genetic Technologies Corporation 20
Arrowhead Pharmaceuticals, Inc. 21
Carolus Therapeutics, Inc. 22
Cevec Pharmaceuticals GmbH 23
Dicerna Pharmaceuticals, Inc. 24
Digna Biotech, S.L. 25
Editas Medicine, Inc. 26
Grifols, S.A. 27
Inhibrx 28
Intellia Therapeutics, Inc. 29
International Stem Cell Corporation 30
Ionis Pharmaceuticals, Inc. 31
Kamada Ltd. 32
Polyphor Ltd. 33
ProMetic Life Sciences Inc. 34
rEVO Biologics, Inc. 35
Sangamo BioSciences, Inc. 36
Alpha- Antitrypsin Deficiency - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ALN-AAT - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
alpha-1 proteinase inhibitor (human) - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
alpha-1 proteinase inhibitor (human) second generation - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ANN-001 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ARC-AAT - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CT-2009 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
DB-027 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Drugs for Alpha-1 Antitrypsin Deficiency - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
ISIS-AATRx - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Oligonucleotides to Inhibit Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
POL-6014 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
rAAV2-CB-hAAT - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Recombinant A1PI - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Recombinant Human Alpha-1 Antitrypsin - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Recombinant Human Alpha-1 Antitrypsin Replacement for Alpha-Antitrypsin Deficiency - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Recombinant Protein for Alpha-1 Antitrypsin Deficiency - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
RNAi Oligonucleotide for Alpha-1 Antitrypsin Deficiency and Liver Disease - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Alpha- Antitrypsin Deficiency - Dormant Projects 78
Alpha- Antitrypsin Deficiency - Discontinued Products 79
Alpha- Antitrypsin Deficiency - Product Development Milestones 80
Featured News & Press Releases 80
May 11, 2016: Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates 80
May 05, 2016: Investigational Gene-Based Therapy for Alpha-1 Antitrypsin Deficiency Demonstrates Durable Response at Five Years 81
Feb 25, 2016: Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates 81
Jan 20, 2016: AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Alpha-1 Antitrypsin Deficiency 82
Jan 19, 2016: Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation 83
Dec 08, 2015: Kamada Completes Enrollment of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of AAT Deficiency 83
Nov 09, 2015: Sangamo BioSciences Announces Publication Of Improved Method For Efficient Targeted Integration In Hematopoietic Stem Cells And T-cells 84
Jul 08, 2015: Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand 85
Jul 02, 2015: Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency 85
Jun 10, 2015: Arrowhead Receives Orphan Drug Designation for ARC-AAT 86
May 20, 2015: Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency 86
May 05, 2015: Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT 88
Apr 20, 2015: Kamada Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency 89
Feb 23, 2015: Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency 92
Jan 07, 2015: Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables

Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Alpha- Antitrypsin Deficiency - Pipeline by Adverum Biotechnologies, Inc., H2 2016 18
Alpha- Antitrypsin Deficiency - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 19
Alpha- Antitrypsin Deficiency - Pipeline by Applied Genetic Technologies Corporation, H2 2016 20
Alpha- Antitrypsin Deficiency - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016 21
Alpha- Antitrypsin Deficiency - Pipeline by Carolus Therapeutics, Inc., H2 2016 22
Alpha- Antitrypsin Deficiency - Pipeline by Cevec Pharmaceuticals GmbH, H2 2016 23
Alpha- Antitrypsin Deficiency - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 24
Alpha- Antitrypsin Deficiency - Pipeline by Digna Biotech, S.L., H2 2016 25
Alpha- Antitrypsin Deficiency - Pipeline by Editas Medicine, Inc., H2 2016 26
Alpha- Antitrypsin Deficiency - Pipeline by Grifols, S.A., H2 2016 27
Alpha- Antitrypsin Deficiency - Pipeline by Inhibrx, H2 2016 28
Alpha- Antitrypsin Deficiency - Pipeline by Intellia Therapeutics, Inc., H2 2016 29
Alpha- Antitrypsin Deficiency - Pipeline by International Stem Cell Corporation, H2 2016 30
Alpha- Antitrypsin Deficiency - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 31
Alpha- Antitrypsin Deficiency - Pipeline by Kamada Ltd., H2 2016 32
Alpha- Antitrypsin Deficiency - Pipeline by Polyphor Ltd., H2 2016 33
Alpha- Antitrypsin Deficiency - Pipeline by ProMetic Life Sciences Inc., H2 2016 34
Alpha- Antitrypsin Deficiency - Pipeline by rEVO Biologics, Inc., H2 2016 35
Alpha- Antitrypsin Deficiency - Pipeline by Sangamo BioSciences, Inc., H2 2016 36
Assessment by Monotherapy Products, H2 2016 37
Number of Products by Stage and Target, H2 2016 39
Number of Products by Stage and Mechanism of Action, H2 2016 41
Number of Products by Stage and Route of Administration, H2 2016 43
Number of Products by Stage and Molecule Type, H2 2016 45
Alpha- Antitrypsin Deficiency - Dormant Projects, H2 2016 78
Alpha- Antitrypsin Deficiency - Discontinued Products, H2 2016 79

List of Figures

Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 37
Number of Products by Targets, H2 2016 38
Number of Products by Stage and Targets, H2 2016 38
Number of Products by Mechanism of Actions, H2 2016 40
Number of Products by Stage and Mechanism of Actions, H2 2016 40
Number of Products by Routes of Administration, H2 2016 42
Number of Products by Stage and Routes of Administration, H2 2016 42
Number of Products by Molecule Types, H2 2016 44
Number of Products by Stage and Molecule Types, H2 2016 44
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Travelers Vaccines Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 24-May-2017        Price: US 3480 Onwards        Pages: 135
    A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later enc......
  • Global Head Lice Infestation Drug Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 23-May-2017        Price: US 3480 Onwards        Pages: 120
    Head lice are tiny wingless insects that do not fly or jump, their primary means of movement is crawling. The main way lice are spread is head to head contact. Lice are human parasites that feed on the blood of the infested person. Head Lice Infestation Drug is to kill lice or kill eggs. Scope of the Report: In the last several years, global market of Head Lice Infestation Drug developed stable, with an average growth rate of 4.25%. In 2015, global re......
  • Global Pneumococcal Vaccine Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 23-May-2017        Price: US 3480 Onwards        Pages: 121
    Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines. 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK). In the last several years, global market of Pneumococcal Vaccine developed rapidly generally, while global production g......
  • Global Cough Medicine Market Research Report 2017
    Published: 23-May-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Cough Medicine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cough Medicine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • 2017-2022 United States Nicotine Gum Market Report (Status and Outlook)
    Published: 22-May-2017        Price: US 3360 Onwards        Pages: 115
    "This report will be delivered in 2-3 business days after the order is placed." The Nicotine Gum market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top players include - Novartis - Perrigo Company - Pfizer - Fertin Pharma - GlaxoSmithKline - Revolymer - Johnson &......
  • 2017-2022 China Caffeine Market Report (Status and Outlook)
    Published: 22-May-2017        Price: US 3360 Onwards        Pages: 114
    "This report will be delivered in 2-3 business days after the order is placed." The Caffeine market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include - CSPC - BASF - Shandong Xinhua - Kudos Chemie Limited - Aarti Healthcare - Zhongan Pharmaceutical - Jilin Shulan......
  • 2017-2022 Global Top Countries Caffeine Market Report
    Published: 22-May-2017        Price: US 4960 Onwards        Pages: 154
    "This report will be delivered in 2-3 business days after the order is placed." The Global Caffeine market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Caffeine in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and ......
  • 2017-2022 India Caffeine Market Report (Status and Outlook)
    Published: 22-May-2017        Price: US 3360 Onwards        Pages: 114
    "This report will be delivered in 2-3 business days after the order is placed." The Caffeine market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In India market, the top players include - CSPC - BASF - Shandong Xinhua - Kudos Chemie Limited - Aarti Healthcare - Zhongan Pharmaceutical - Jilin Shulan......
  • 2017-2022 Japan Caffeine Market Report (Status and Outlook)
    Published: 22-May-2017        Price: US 3360 Onwards        Pages: 114
    "This report will be delivered in 2-3 business days after the order is placed." The Caffeine market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include - CSPC - BASF - Shandong Xinhua - Kudos Chemie Limited - Aarti Healthcare - Zhongan Pharmaceutical - Jilin Shulan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs